Dec. 30 at 5:49 PM
$BOLD - Extreme Valuation Disconnect
There is a massive gap between the current share price and what Wall Street analysts believe the company is worth.
• Current Price: ~
$1.20 –
$1.30.
• Analyst Targets: The average price target is
$3.50 to
$4.00, representing an upside of 170% to 230%.
• The "Asymmetry": At these levels, the downside is relatively limited (close to the cash value), while the upside—if clinical data is positive—could be a 5x or 10x return over the next 24 months.
## 4. Imminent "Proof-of-Concept" Catalysts
The stock is attractive now because the "wait" is almost over. We are entering a 12-month window of major data releases:
• H2 2025 (Now): Preliminary safety and anti-tumor data from the POTENTIATE trial.
• H1 2026: Moving their second drug, BBI-940, into human trials.
• The Synergy: Investors are specifically excited about the combination of BBI-355 and BBI-825, which showed "synergistic" tumor regression in animal models without increasing toxicity.
